title: Prevention of recurrent ischemic stroke.
abstract: Recurrent ischemic stroke and transient ischemic attack are common problems in primary care, with stroke survivors averaging 10 outpatient visits per year. Risk factors such as hypertension, diabetes, and hypercholesterolemia should be evaluated during each office visit. Attention should be given to lifestyle modification including management of obesity, smoking cessation, reduction in alcohol consumption, and promotion of physical activity. The choice of an antiplatelet agent (e.g., aspirin, ticlopidine, clopidogrel, dipyridamole) or the anticoagulant warfarin is based on the safety, tolerability, effectiveness, and price of each agent. Aspirin is a common first choice for prevention of recurrent stroke, but the combination of dipyridamole and aspirin should be considered for many patients because of its superior effectiveness in two clinical trials. Clopidogrel is recommended for patients with aspirin intolerance or allergy, or for those who cannot tolerate dipyridamole. Warfarin and the combination of aspirin and clopidogrel should not be used in the prevention of ischemic stroke. Carotid endarterectomy is appropriate for select patients; carotid stenting was recently shown to be less effective and less safe than endarterectomy.
authors: Trident Medical Center/Medical University of South Carolina Family Medicine Residency Program, Charleston, South Carolina 29406, USA. macfarll@musc.edu
authors: Lori M
authors: LM
authors: Dickerson
authors: Peter J
authors: PJ
authors: Carek
authors: Robert Glen
authors: RG
authors: Quattlebaum
mesh_terms: D000800:Angioplasty, Balloon; D002545:Brain Ischemia / Q000150:complications / Q000517:prevention & control*; D002340:Carotid Artery Diseases / Q000628:therapy; D016894:Endarterectomy, Carotid; D006401:Hematologic Agents / Q000627:therapeutic use; D006801:Humans; D012307:Risk Factors; D055502:Secondary Prevention; D015607:Stents; D020521:Stroke / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D015912:Thrombolytic Therapy
chemical_list: D006401:Hematologic Agents